Takeda and Metabolon Initiate Research Collaboration
News Apr 18, 2012
Metabolon, Inc. has announced that Metabolon and Takeda Pharmaceutical Company Limited have formed a multiyear research alliance that will focus on discovering therapeutic targets and biomarkers.
Metabolon has developed a proprietary analytical platform and software for biomarker discovery using metabolomics to accelerate drug discovery and development by accurately measuring the spectrum of biochemical changes in biological samples, and mapping these changes to their corresponding metabolic pathways.
Metabolon will apply its platform to discover and validate targets, and identify novel pharmacodynamic biomarkers for translation into the clinic.
Metabolon’s CEO John Ryals said, “We are excited about the prospect of collaborating with Takeda to accelerate its research programs. Metabolon has built a unique platform and has accumulated a vast amount of institutional knowledge in the field of metabolome analysis. We believe that integrating metabolomic profiling into Takeda’s R&D programs may lead to novel therapies and more informed decisions.
A Mystery Solved: "Protein Cluedo" Reveals Enzyme SecretsNews
Scientists have used biosensors to solve questions about protein production which might seem familiar to mystery board game enthusiasts.READ MORE
Studying Ebola-Host Cell Interaction Helps Find Targets for Antiviral DrugsNews
In some ways, the Ebola virus operates like a vampire; only after it is politely invited in to a host cell does it take up the task of destroying everything in its path. In a new study researchers seek to elucidate quantitatively the biomechanical mechanism of Ebola-host cell interaction, providing potential new targets for antiviral drug development.READ MORE